NorthView Acquisition Corp - Units (1 Ord & 1 Right & 1/2 War)
NVACU
Get informed when a big investor buys or sells
+ FollowMarket Cap$78.44M
Close$
Share Statistics
| Market cap | $78.44 Million |
|---|---|
| Enterprise Value | $91.84 Million |
| Dividend Yield | $NaN (NaN%) |
| Earnings per Share | $- |
| Beta | - |
| Outstanding Shares | - |
Return
| Return on Equity | 135.33% |
|---|---|
| Return on Assets | -4426.81% |
| Return on Invested Capital | 110.55% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -2.95 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.15 |
| Debt to Equity | -0.49 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Profusa, Inc. Common Stock
2 employees
CEO: Ben Chung-Bin Hwang A digital-health company developing tissue-integrating biosensors (e.g. the Lumee™ Oxygen Platform) to continuously monitor body chemistry and provide AI-powered health insights, targeting chronic conditions such as diabetes and critical limb ischemia